Immunome (IMNM) AI Stock Analysis

• Market Cap: $1.37B
• Dividend Yield: N/A
• Average Volume (3M): 1.64M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.67
• Revenue Growth: 16.74%
• EPS Growth: 59.89%
• Country: US
• Employees: 131
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.50
• Shares Outstanding: 87,045,006
• 10 Day Avg. Volume: 1,187,610
• 30 Day Avg. Volume: 1,641,610
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.40
• Enterprise Value/Revenue: 43.32
• Enterprise Value/Gross Profit: 43.32
• Enterprise Value/Ebitda: -2.90
• 1Y Price Target: $22.33
• Price Target Upside: 42.32% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 11

• Rating: 55 Neutral
• Price Target: $16.50 ▲(5.16% Upside)

Immunome's stock score is primarily influenced by its challenging financial performance, with persistent losses and negative profitability metrics. However, the stock's strong technical indicators suggest bullish momentum, providing a positive offset. The valuation remains unattractive due to negative earnings and no dividend yield, further impacting the overall score.

Positive Factors

Revenue Growth

Consistent revenue growth indicates increasing market acceptance of Immunome's therapies, suggesting potential for long-term expansion and stability in the biotechnology sector.

Cash Flow Improvement

Improving cash generation capabilities enhance Immunome's ability to fund R&D and operational activities, supporting sustained business development and financial health.

Low Leverage

Minimal leverage reduces financial risk, providing Immunome with greater flexibility to invest in growth opportunities and navigate industry challenges without significant debt burden.

Negative Factors

Negative Profitability

Persistent losses impact Immunome's profitability, challenging its ability to achieve sustainable financial performance and potentially limiting reinvestment in growth initiatives.

Operational Inefficiencies

Operational inefficiencies reflected in negative margins may hinder Immunome's capacity to improve profitability, necessitating strategic adjustments to enhance operational effectiveness.

Negative Return on Equity

A negative return on equity indicates significant losses relative to shareholder equity, posing challenges for investor confidence and long-term shareholder value creation.

Immunome Business Overview & Revenue Model

Company Description

Immunome, Inc. (IMNM) is a biotechnology company focused on developing innovative antibody-based therapies for cancer and other serious diseases. Utilizing its proprietary discovery platform, the company identifies and develops therapeutic candidates derived from the immune response of patients. Immunome aims to address unmet medical needs by creating targeted treatments that harness the body's own immune system to combat disease.

How the Company Makes Money

Immunome generates revenue primarily through the development and commercialization of its therapeutic candidates, which are designed to address specific disease indications. The company may earn income through various streams, including milestone payments from partnerships with pharmaceutical companies, royalties from product sales once therapies are commercialized, and funding from grants or government contracts aimed at supporting research and development efforts. Significant collaborations with larger pharmaceutical companies can also provide upfront payments and additional funding tied to the achievement of development milestones, significantly contributing to the company's financial stability and growth.

Immunome Financial Statement Overview

Summary

Immunome faces substantial financial difficulties, with persistent losses impacting profitability and cash flow. While the balance sheet remains robust due to strong equity, operational inefficiencies need addressing to improve financial health.

Income Statement

Immunome's income statement reflects significant challenges, with consistent net losses and negative EBIT and EBITDA margins over the periods reported. Despite some revenue growth from 2024 to TTM (Trailing-Twelve-Months), the company operates with negative profitability metrics, indicating ongoing operational difficulties.

Balance Sheet

The balance sheet shows a strong equity base with a favorable debt-to-equity ratio, suggesting financial stability. However, the company’s high cash position is offset by recurring net losses, which could pressure equity if operations do not improve.

Cash Flow

Immunome's cash flow statement highlights negative operating cash flows, though financing activities have supported liquidity. Free cash flow is persistently negative, which is concerning for long-term sustainability unless the trend reverses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	12.59M	9.04M	14.02M	0.00	0.00	0.00
Gross Profit	12.59M	9.04M	14.02M	-631.00K	-755.00K	-755.00K
EBITDA	-187.92M	-151.35M	-28.00M	-36.27M	-23.95M	-17.04M
Net Income	-212.39M	-292.96M	-106.81M	-37.51M	-24.71M	-17.84M
Balance Sheet
Total Assets	296.29M	240.24M	148.54M	24.05M	57.92M	44.52M
Cash, Cash Equivalents and Short-Term Investments	268.04M	217.30M	138.14M	20.32M	49.23M	39.77M
Total Debt	4.14M	4.83M	1.65M	291.00K	317.00K	613.00K
Total Liabilities	27.02M	59.08M	28.66M	7.39M	9.74M	3.18M
Stockholders Equity	269.27M	181.16M	119.88M	16.65M	48.19M	41.34M
Cash Flow
Free Cash Flow	-186.17M	-117.97M	-8.40M	-28.94M	-18.30M	-12.72M
Operating Cash Flow	-178.68M	-110.79M	-7.57M	-28.69M	-18.23M	-12.13M
Investing Cash Flow	-25.23M	-85.06M	-30.48M	-248.00K	-79.00K	-586.00K
Financing Cash Flow	182.56M	240.53M	116.41M	32.00K	27.77M	49.94M

Immunome Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 15.69
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMNM, the sentiment is Positive. The current price of 15.69 is above the 20-day moving average (MA) of 14.57, above the 50-day MA of 11.77, and above the 200-day MA of 9.73, indicating a bullish trend. The MACD of 1.41 indicates Negative momentum. The RSI at 66.63 is Neutral, neither overbought nor oversold. The STOCH value of 67.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IMNM.

Immunome Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TSHA	―	$1.30B	―	-51.86%	―	-37.09%	58.96%
IMNM	―	$1.37B	―	-81.20%	―	16.74%	59.89%
IMTX	―	$1.24B	―	-17.34%	―	83.36%	22.27%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GERN	―	$791.14M	-9.66	-31.09%	―	11877.28%	63.14%
TNGX	―	$833.90M	―	-76.09%	―	-42.84%	-17.32%
SANA	―	$1.45B	―	-109.12%	―	―	7.58%

Immunome Corporate Events

Immunome Advances Cancer Therapy Pipeline Amid Financial Loss

Immunome, Inc. is a biotechnology company specializing in the development of targeted cancer therapies, with a focus on first-in-class and best-in-class treatments in the oncology sector. The company is advancing a diverse portfolio of therapeutics, including antibody-drug conjugate therapies.